{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T16:42:35Z","timestamp":1740156155296,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"DOI":"10.1007\/s12664-024-01597-z","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T06:02:31Z","timestamp":1716444151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of serum endotoxin, FGF19, TLR2, TNF-\u03b1, IL-12 and IL-10 in NAFLD-associated T2DM pathogenesis: Insights into Th1 bias and protective mechanisms"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5847-9788","authenticated-orcid":false,"given":"Snigdha Jyoti","family":"Das","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barsha","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangit","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3606-958X","authenticated-orcid":false,"given":"Sujoy","family":"Bose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2722-7171","authenticated-orcid":false,"given":"Purabi Deka","family":"Bose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"1597_CR1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/cld.1141","volume":"18","author":"A De","year":"2021","unstructured":"De A, Duseja A. Nonalcoholic fatty liver disease: Indian perspective. Clin Liver Dis (Hoboken). 2021;18:158\u201363. https:\/\/doi.org\/10.1002\/cld.1141.","journal-title":"Clin Liver Dis (Hoboken)."},{"key":"1597_CR2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.4103\/ijcm.ijcm_437_22","volume":"48","author":"MC Anton","year":"2023","unstructured":"Anton MC, Shanthi B, Sridevi C. Prevalence of non-alcoholic fatty liver disease in urban adult population in a tertiary care center, Chennai. Indian J Community Med. 2023;48:601\u20134. https:\/\/doi.org\/10.4103\/ijcm.ijcm_437_22.","journal-title":"Chennai. Indian J Community Med."},{"key":"1597_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1101\/sqb.2011.76.010710","volume":"76","author":"S Kir","year":"2011","unstructured":"Kir S, Kliewer SA, Mangelsdorf DJ. Roles of FGF19 in liver metabolism. Cold Spring Harb Symp Quant Biol. 2011;76:139\u201344. https:\/\/doi.org\/10.1101\/sqb.2011.76.010710.","journal-title":"Cold Spring Harb Symp Quant Biol."},{"key":"1597_CR4","doi-asserted-by":"publisher","unstructured":"Liu Y, Cao M, Cai Y, Li X, Zhao C, Cui R. Dissecting the role of the FGF19-FGFR4 signaling pathway in cancer development and progression. Front Cell Dev Biol. 2020;8:95. https:\/\/doi.org\/10.3389\/fcell.2020.00095.","DOI":"10.3389\/fcell.2020.00095"},{"key":"1597_CR5","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1210\/jc.2018-01573","volume":"104","author":"SZ Lutz","year":"2019","unstructured":"Lutz SZ, Hennige AM, Peter A, et al. The Gly385 (388) Arg polymorphism of the FGFR4 receptor regulates hepatic lipogenesis under healthy diet. J Clin Endocrinol Metab. 2019;104:2041\u201353. https:\/\/doi.org\/10.1210\/jc.2018-01573.","journal-title":"J Clin Endocrinol Metab."},{"key":"1597_CR6","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1080\/10408398.2021.1966738","volume":"63","author":"H Han","year":"2023","unstructured":"Han H, Jiang Y, Wang M, et al. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis. Crit Rev Food Sci Nutr. 2023;63:1689\u201306. https:\/\/doi.org\/10.1080\/10408398.2021.1966738.","journal-title":"Crit Rev Food Sci Nutr."},{"key":"1597_CR7","doi-asserted-by":"publisher","unstructured":"Harte AL, da Silva NF, Creely SJ, et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond). 2010;7:15. https:\/\/doi.org\/10.1186\/1476-9255-7-15.","DOI":"10.1186\/1476-9255-7-15"},{"key":"1597_CR8","doi-asserted-by":"publisher","first-page":"7381","DOI":"10.3748\/wjg.v20.i23.7381","volume":"20","author":"K Miura","year":"2014","unstructured":"Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:7381\u201391. https:\/\/doi.org\/10.3748\/wjg.v20.i23.7381.","journal-title":"World J Gastroenterol."},{"key":"1597_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s12291-016-0616-3","volume":"32","author":"P Mohan","year":"2017","unstructured":"Mohan P, Sundar V, Bhaskar E, Anthony S. Estimation of upper limit of normal for serum alanine transaminase in healthy South Indian population. Indian J Clin Biochem. 2017;32:337\u201342. https:\/\/doi.org\/10.1007\/s12291-016-0616-3.","journal-title":"Indian J Clin Biochem."},{"key":"1597_CR10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i47.8263","author":"BJ Perumpail","year":"2017","unstructured":"Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.\u00a0World J Gastroenterol. 2017;23:8263\u201376.\u00a0https:\/\/doi.org\/10.3748\/wjg.v23.i47.8263.","journal-title":"World J Gastroenterol"},{"key":"1597_CR11","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739\u201352. https:\/\/doi.org\/10.1016\/S2468-1253(20)30077-7.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"1597_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S1665-2681(19)31922-2","volume":"6","author":"D Amarapurkar","year":"2007","unstructured":"Amarapurkar D, Kamani P, Patel N,\u00a0 et al. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol. 2007;6:161\u20133.","journal-title":"Ann Hepatol"},{"issue":"2","key":"1597_CR13","first-page":"76","volume":"25","author":"SP Singh","year":"2004","unstructured":"Singh SP, Nayak S, Swain M, et al. Prevalence of nonalcoholic fatty liver disease in coastal eastern India: a preliminary ultrasonographic survey. Trop Gastroenterol. 2004;25:76\u20139.","journal-title":"Trop Gastroenterol"},{"key":"1597_CR14","doi-asserted-by":"crossref","unstructured":"Akdeniz Odemis D, Tuncer SB,\u00a0Adamnejad Ghafour A, et al. FGFR4 c.1162G\u2009>\u2009A (p.Gly388Arg) Polymorphism analysis in Turkish patients with retinoblastoma. J Oncol. 2020;2020:9401038.","DOI":"10.1155\/2020\/9401038"},{"issue":"3","key":"1597_CR15","first-page":"840","volume":"62","author":"J Bange","year":"2002","unstructured":"Bange J, Prechtl D, Cheburkin Y, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg388 allele. Can Res. 2002;62:840\u20137.","journal-title":"Can Res"},{"key":"1597_CR16","doi-asserted-by":"publisher","unstructured":"Schreuder TC, Marsman HA, Lenicek M, et al. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol. 2010;298:G440\u20135. https:\/\/doi.org\/10.1152\/ajpgi.00322.2009.","DOI":"10.1152\/ajpgi.00322.2009"},{"key":"1597_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.805722","author":"MN Yang","year":"2022","unstructured":"Yang MN, Huang R, Liu X, et al. Fibroblast growth factor 19 in gestational diabetes mellitus and fetal growth.\u00a0Front Endocrinol (Lausanne). 2022;12:805722.\u00a0https:\/\/doi.org\/10.3389\/fendo.2021.805722.","journal-title":"Front Endocrinol"},{"key":"1597_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113206","author":"KM Anderson","year":"2021","unstructured":"Anderson KM, Gayer CP. The pathophysiology of farnesoid X receptor (FXR) in the GI tract: inflammation, barrier function and innate immunity.\u00a0Cells. 2021;10:3206. \u00a0https:\/\/doi.org\/10.3390\/cells10113206.","journal-title":"Cells"},{"issue":"4","key":"1597_CR19","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000496687","volume":"100","author":"T Horikawa","year":"1963","unstructured":"Horikawa T, Oshima T, Li M,\u00a0 et al. Chenodeoxycholic acid releases pro-inflammatory cytokines from small intestinal epithelial cells through the farnesoid X receptor. Gastroenterologia. 1963;100:286\u201394.","journal-title":"Gastroenterologia"},{"key":"1597_CR20","first-page":"1664","volume":"5","author":"Meli Rosaria","year":"2014","unstructured":"Meli R, Mattace Raso G, Calignano A. Role of innate immune response in non-alcoholic fatty liver disease: metabolic complications and therapeutic tools.\u00a0Front Immunol. 2014;5:177.","journal-title":"Front Immunol"},{"key":"1597_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1145392","author":"C Huang","year":"2023","unstructured":"Huang C, Zhou Y, Cheng J, et al. Pattern recognition receptors in the development of nonalcoholic fatty liver disease and progression to hepatocellular carcinoma: an emerging therapeutic strategy.\u00a0 Front Endocrinol (Lausanne). 2023;14:1145392.\u00a0https:\/\/doi.org\/10.3389\/fendo.2023.1145392.","journal-title":"Front Endocrinol"},{"key":"1597_CR22","doi-asserted-by":"publisher","unstructured":"Kessoku T, Kobayashi T, Imajo K, et al. Endotoxins and non-alcoholic fatty liver disease. Front Endocrinol (Lausanne). 2021;12:770986. https:\/\/doi.org\/10.3389\/fendo.2021.770986.","DOI":"10.3389\/fendo.2021.770986"},{"key":"1597_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2478\/rjim-2020-0029","volume":"59","author":"D Darmadi","year":"2021","unstructured":"Darmadi D, Riska R. Association between serum interleukin (IL)-12 level and severity of non-alcoholic fatty liver disease (NAFLD). Rom J Intern Med. 2021;59:66\u201372. https:\/\/doi.org\/10.2478\/rjim-2020-0029.","journal-title":"Rom J Intern Med."},{"key":"1597_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21114189","author":"T Auguet","year":"2020","unstructured":"Auguet T, Bertran L, Binetti J, et al. Relationship between IL-8 circulating levels and TLR2 hepatic expression in women with morbid obesity and nonalcoholic steatohepatitis.\u00a0 Int J Mol Sci. 2020;21:4189. \u00a0https:\/\/doi.org\/10.3390\/ijms21114189.","journal-title":"Int J Mol Sci"},{"key":"1597_CR25","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3748\/wjg.v12.i11.1681","volume":"12","author":"LJ Zhang","year":"2006","unstructured":"Zhang LJ, Wang XZ. Interleukin-10 and chronic liver disease. World J Gastroenterol. 2006;12:1681\u20135. https:\/\/doi.org\/10.3748\/wjg.v12.i11.1681.","journal-title":"World J Gastroenterol."},{"key":"1597_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/liv.12315","volume":"34","author":"V Kesar","year":"2014","unstructured":"Kesar V, Odin JA. Toll-like receptors and liver disease. Liver Int. 2014;34:184\u201396. https:\/\/doi.org\/10.1111\/liv.12315.","journal-title":"Liver Int."},{"key":"1597_CR27","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1038\/s41388-018-0591-7","volume":"38","author":"L Gao","year":"2019","unstructured":"Gao L, Lang L, Zhao X, et al. FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19\/FGFR4 signaling in head and neck squamous cell carcinoma. Oncogene. 2019;38:2394\u2013404. https:\/\/doi.org\/10.1038\/s41388-018-0591-7.","journal-title":"Oncogene"},{"key":"1597_CR28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","volume":"7","author":"SA Harrison","year":"2022","unstructured":"Harrison SA, Abdelmalek MF, Neff G,\u00a0 et al. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2022;7:603\u201316.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1597_CR29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","volume":"160","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Neff G, Guy CD,\u00a0 et al. Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis. Gastroenterology. 2021;160:219\u201331.","journal-title":"Gastroenterology"},{"key":"1597_CR30","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1002\/hep.30590","volume":"71","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Rossi SJ, Paredes AH,\u00a0 et al. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis. Hepatology. 2020;71:1198\u2013212.","journal-title":"Hepatology"},{"key":"1597_CR31","doi-asserted-by":"publisher","unstructured":"Tian H, Zhang S, Liu Y, Wu Y, Zhang D. Fibroblast growth factors for nonalcoholic fatty liver disease: opportunities and challenges. Int J Mol Sci. 2023;24:4583. https:\/\/doi.org\/10.3390\/ijms24054583.","DOI":"10.3390\/ijms24054583"}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-024-01597-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12664-024-01597-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-024-01597-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T06:41:10Z","timestamp":1716446470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12664-024-01597-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":31,"alternative-id":["1597"],"URL":"https:\/\/doi.org\/10.1007\/s12664-024-01597-z","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"type":"print","value":"0254-8860"},{"type":"electronic","value":"0975-0711"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"22 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SJD, BP, SD, SB and PDB declare that there is no conflict of interest regarding the publication of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce any previously published material and patient permission to publish photographs"}},{"value":"The study was performed conforming to the Helsinki Declaration of 1975, as\u00a0revised in 2000 and 2008 concerning human and animal rights, and the authors followed the policy concerning informed consent as\u00a0shown on Springer.com.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Ethical approval from the Institutional Ethics Committee of Gauhati Medical College and Cotton University has been taken and will be provided if required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Required consent has been duly taken and will be provided if required.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"The manuscript is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright holder.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Submission declaration and verification"}},{"value":"The authors are solely responsible for the data and the content of the\u00a0paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology or the printer\/publishers are responsible for the results\/findings and content of this article.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}